ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Evero DCB

Its studies are mostly in Peripheral Arterial Disease, led by Cook Group.

Furthest: no phase, since Aug 20, 20251 company-led study, 1 open or runningNext primary completion: Sep 2028

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cook Group11 open or runningno phasesince Aug 20, 2025Aug 20, 2025Sep 2028NCT07144150

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2025First study: no phase study in Peripheral Vascular DiseasesFirst studyNCT07144150 · 410 planned · United States

Ahead

  1. Sep 2028Primary completion: no phase study in Peripheral Vascular DiseasesNCT07144150

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07144150Peripheral Vascular Diseases · United States–RecruitingSep 2028410

How it is read

Names in the registry

  • “Evero DCB”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.